[go: up one dir, main page]

HK1021623A1 - Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases. - Google Patents

Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.

Info

Publication number
HK1021623A1
HK1021623A1 HK00100645A HK00100645A HK1021623A1 HK 1021623 A1 HK1021623 A1 HK 1021623A1 HK 00100645 A HK00100645 A HK 00100645A HK 00100645 A HK00100645 A HK 00100645A HK 1021623 A1 HK1021623 A1 HK 1021623A1
Authority
HK
Hong Kong
Prior art keywords
cyclooxygenase
compositions
once
mediated diseases
day treatment
Prior art date
Application number
HK00100645A
Other languages
English (en)
Inventor
Bruno Hancock
Conrad Winters
Barry Gertz
Elliot Ehrich
Original Assignee
Merck & Co Inc
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1021623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co Inc, Merck Frosst Canada Inc filed Critical Merck & Co Inc
Publication of HK1021623A1 publication Critical patent/HK1021623A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK00100645A 1996-05-17 2000-02-02 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases. HK1021623A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (en) 1996-05-17 1997-05-13 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases

Publications (1)

Publication Number Publication Date
HK1021623A1 true HK1021623A1 (en) 2000-06-23

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00100645A HK1021623A1 (en) 1996-05-17 2000-02-02 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.

Country Status (29)

Country Link
US (1) US6063811A (xx)
EP (1) EP0910368A1 (xx)
JP (1) JPH11512754A (xx)
KR (1) KR100373622B1 (xx)
CN (1) CN1140267C (xx)
AR (1) AR012014A1 (xx)
AU (1) AU3004997A (xx)
BG (1) BG103000A (xx)
BR (1) BR9709097A (xx)
CA (1) CA2254061C (xx)
CO (1) CO5050370A1 (xx)
CZ (1) CZ291463B6 (xx)
DZ (1) DZ2200A1 (xx)
EA (1) EA001596B1 (xx)
EE (1) EE03746B1 (xx)
HK (1) HK1021623A1 (xx)
HR (1) HRP970262A2 (xx)
HU (1) HUP9902889A3 (xx)
ID (1) ID16921A (xx)
IL (1) IL126899A (xx)
IS (1) IS4891A (xx)
MY (1) MY116201A (xx)
NO (1) NO985342D0 (xx)
NZ (1) NZ332670A (xx)
PE (1) PE66998A1 (xx)
PL (1) PL188649B1 (xx)
SK (1) SK284330B6 (xx)
TR (1) TR199802345T2 (xx)
WO (1) WO1997044028A1 (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322824A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
PL355391A1 (en) * 1999-12-22 2004-04-19 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
CA2411960C (en) 2000-06-13 2010-10-12 Wyeth Analgesic and anti-inflammatory compositions containing cox-2 inhibitors
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
NZ524124A (en) * 2000-08-18 2004-09-24 Pharmacia Corp Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
PE20020351A1 (es) * 2000-09-11 2002-06-14 Novartis Ag Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2445502A1 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
IL160855A0 (en) * 2001-09-26 2004-08-31 Pharmacia Corp Intraorally disintegrating valdecoxib compositions
OA12666A (en) * 2001-10-10 2006-06-19 Pharmacia Corp Corporate Paten Intraorally disintegrating valdecoxib compositionsprepared by spray drying process.
BR0308156A (pt) * 2002-03-07 2005-01-04 Novartis Ag Composições farmacêuticas sólidas contendo lumiracoxib
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
JP7291220B2 (ja) 2018-11-21 2023-06-14 トレモ― ファーマシューティカルズ，インコーポレーテッド ロフェコキシブの精製形態、製造方法および使用
US20200323830A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SG43841A1 (en) * 1994-01-10 1997-11-14 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
CZ373898A3 (cs) 1999-06-16
EE03746B1 (et) 2002-06-17
SK284330B6 (sk) 2005-01-03
HRP970262A2 (en) 1998-06-30
NO985342L (no) 1998-11-16
EP0910368A1 (en) 1999-04-28
IS4891A (is) 1998-11-10
US6063811A (en) 2000-05-16
MY116201A (en) 2003-11-28
TR199802345T2 (xx) 1999-03-22
IL126899A0 (en) 1999-09-22
EA199801017A1 (ru) 1999-04-29
SK156798A3 (en) 2000-01-18
CN1140267C (zh) 2004-03-03
BR9709097A (pt) 1999-08-03
CN1225010A (zh) 1999-08-04
CZ291463B6 (cs) 2003-03-12
PE66998A1 (es) 1998-10-24
CO5050370A1 (es) 2001-06-27
DZ2200A1 (fr) 2004-06-20
AU3004997A (en) 1997-12-09
PL188649B1 (pl) 2005-03-31
IL126899A (en) 2004-03-28
PL329940A1 (en) 1999-04-26
KR100373622B1 (ko) 2003-07-12
NZ332670A (en) 2000-07-28
JPH11512754A (ja) 1999-11-02
KR20000011082A (ko) 2000-02-25
HUP9902889A2 (hu) 2002-01-28
HUP9902889A3 (en) 2002-04-29
WO1997044028A1 (en) 1997-11-27
ID16921A (id) 1997-11-20
AR012014A1 (es) 2000-09-27
BG103000A (en) 1999-09-30
NO985342D0 (no) 1998-11-16
CA2254061C (en) 2003-12-02
EE9800393A (et) 1999-06-15
CA2254061A1 (en) 1997-11-27
EA001596B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
HK1021623A1 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
HK1023119A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
IL115470A (en) Therapeutic food composition
IL121170A0 (en) Compositions for the treatment of dermatological disorders
ZA971937B (en) Combinations for treatment of proliferative diseases.
AU3107197A (en) Medicinal compositions for treating liver diseases
AU2027495A (en) Pharmaceutical composition for treating hemorrhoidal diseases
HUP9901303A3 (en) A pharmaceutical composition for the treatment of autoimmune diseases
HUP0000954A3 (en) Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy
AU4215499A (en) Treatment of neurodegenerative diseases
ZA977874B (en) Pharmaceutical compositions for treating viral diseases
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
AU3122597A (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
AU2754997A (en) The treatment of plant diseases
AUPN221195A0 (en) Combined waste treatment
ZA974206B (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases.
AUPN727595A0 (en) Therapeutic compositions
AU5854799A (en) Novel treatment of neurodegenerative diseases
GB9612063D0 (en) Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
GB9612065D0 (en) Compositions for a once a day treatment of cyclooxtgenase-2 mediated diseases
AU8242398A (en) Medicinal compositions for treating immunodeficiency diseases
AU7190496A (en) Therapeutic compositions
AU7545998A (en) Treatment of osteoporosis
AU679162B3 (en) Therapeutic compositions

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080513